No-observed-adverse-effect level (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "No-observed-adverse-effect level" in English language version.

refsWebsite
Global rank English rank
2nd place
2nd place
4th place
4th place
11th place
8th place
1st place
1st place
low place
low place
low place
low place
207th place
136th place
low place
low place
3rd place
3rd place
882nd place
600th place

akita-u.ac.jp

med.akita-u.ac.jp

books.google.com

ceaa-acee.gc.ca

doi.org

  • Deshpande, P.; Mohan, V.; Ingavale, D.; Mane, J.; Pore, M.; Thakurdesai Phd, P. (2017). "Preclinical Safety Assessment of Furostanol Glycoside-Based Standardized Fenugreek Seed Extract in Laboratory Rats". Journal of Dietary Supplements. 14 (5): 521–541. doi:10.1080/19390211.2016.1272659. PMID 28156165. S2CID 25932512.
  • Engelhardt JA, Dorato MA (August 2005). "The no-observed-adverse-effect-level in drug safety evaluations: Use, issues, and definition(s)". Regul Toxicol Pharmacol. 42 (3): 265–274. doi:10.1016/j.yrtph.2005.05.004. PMID 15979222.
  • Dorato, MA; Engelhardt, JA (August 2005). "The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s)". Regulatory Toxicology and Pharmacology. 42 (3): 265–74. doi:10.1016/j.yrtph.2005.05.004. PMID 15979222.
  • Dakeishi, M; Murata, K; Tamura, A; Iwata, T (February 2006). "Relation between benchmark dose and no-observed-adverse-effect level in clinical research: Effects of daily alcohol intake on blood pressure in Japanese salesmen" (PDF). Risk Analysis (Submitted manuscript). 26 (1): 115–23. CiteSeerX 10.1.1.555.7381. doi:10.1111/j.1539-6924.2006.00722.x. PMID 16492185. S2CID 24406585.

epa.gov

fsra.net

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Deshpande, P.; Mohan, V.; Ingavale, D.; Mane, J.; Pore, M.; Thakurdesai Phd, P. (2017). "Preclinical Safety Assessment of Furostanol Glycoside-Based Standardized Fenugreek Seed Extract in Laboratory Rats". Journal of Dietary Supplements. 14 (5): 521–541. doi:10.1080/19390211.2016.1272659. PMID 28156165. S2CID 25932512.
  • Engelhardt JA, Dorato MA (August 2005). "The no-observed-adverse-effect-level in drug safety evaluations: Use, issues, and definition(s)". Regul Toxicol Pharmacol. 42 (3): 265–274. doi:10.1016/j.yrtph.2005.05.004. PMID 15979222.
  • Dorato, MA; Engelhardt, JA (August 2005). "The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s)". Regulatory Toxicology and Pharmacology. 42 (3): 265–74. doi:10.1016/j.yrtph.2005.05.004. PMID 15979222.
  • Dakeishi, M; Murata, K; Tamura, A; Iwata, T (February 2006). "Relation between benchmark dose and no-observed-adverse-effect level in clinical research: Effects of daily alcohol intake on blood pressure in Japanese salesmen" (PDF). Risk Analysis (Submitted manuscript). 26 (1): 115–23. CiteSeerX 10.1.1.555.7381. doi:10.1111/j.1539-6924.2006.00722.x. PMID 16492185. S2CID 24406585.

psu.edu

citeseerx.ist.psu.edu

semanticscholar.org

api.semanticscholar.org

  • Deshpande, P.; Mohan, V.; Ingavale, D.; Mane, J.; Pore, M.; Thakurdesai Phd, P. (2017). "Preclinical Safety Assessment of Furostanol Glycoside-Based Standardized Fenugreek Seed Extract in Laboratory Rats". Journal of Dietary Supplements. 14 (5): 521–541. doi:10.1080/19390211.2016.1272659. PMID 28156165. S2CID 25932512.
  • Dakeishi, M; Murata, K; Tamura, A; Iwata, T (February 2006). "Relation between benchmark dose and no-observed-adverse-effect level in clinical research: Effects of daily alcohol intake on blood pressure in Japanese salesmen" (PDF). Risk Analysis (Submitted manuscript). 26 (1): 115–23. CiteSeerX 10.1.1.555.7381. doi:10.1111/j.1539-6924.2006.00722.x. PMID 16492185. S2CID 24406585.

web.archive.org